J Cancer 2018; 9(10):1731-1736. doi:10.7150/jca.24785 This issue Cite

Research Paper

Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires

Ioannis Tremmas1*, George Petsatodis2, Michael Potoupnis3, Stella Laskou4, Dimitrios Giannakidis4, Stylianos Mantalovas4, Charilaos Koulouris4, Athanasios Katsaounis4, Efstathios Pavlidis4, Aikaterini Amaniti5, Haidong Huang6*, Chong Bai6✉, Dongchen Shi6*, Athanasios Dardas8, Paul Zarogoulidis9✉, Chrisanthi Sardeli10, Fotis Konstantinou11, Nikolaos Katsikogiannis12, Konstantinos Zarogoulidis13, Ilias Karapantzos14, Chrysanthi Karapantzou14, Xiaping Shen15*, Isaak Kesisoglou4, Konstantinos Sapalidis4

1. Orthopaedic Department, “Limassol” General Hospital, Cyprus
2. 1st Orthopaedic Surgery Department, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Greece
3. Department of Orthopaedic Surgery, “G. Papageorgiou” General Hospital, Aristotle University of Thessaloniki, Greece
4. 3rd Department of Surgery, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
5. Anesthesiology Department, “AHEPA” University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
6. Department of Respiratory and Critical Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China
7. Department of Respiratory Diseases, The Affiliated Jiangning hospital of Nanjing Medical University, Nanjing, China
8. Scientific co-operator of Immunology - Histocompatibility Laboratory of “G. Papageorgiou” General Hospital, Thessaloniki Greece
9. Pulmonary-Oncology Department, “Theageneio” Cancer Hospital, Thessaloniki, Greece
10. Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece
11. Thoracic Surgery Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
12. Surgery Department (NHS), University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
13. Pulmonary Department-Oncology Unit, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Greece
14. Ear, Nose and Throat Department, “Saint Luke” Private Hospital, Thessaloniki, Panorama, Greece
15. Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai, China
*These authors contributed equally to this work.

Citation:
Tremmas I, Petsatodis G, Potoupnis M, Laskou S, Giannakidis D, Mantalovas S, Koulouris C, Katsaounis A, Pavlidis E, Amaniti A, Huang H, Bai C, Shi D, Dardas A, Zarogoulidis P, Sardeli C, Konstantinou F, Katsikogiannis N, Zarogoulidis K, Karapantzos I, Karapantzou C, Shen X, Kesisoglou I, Sapalidis K. Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires. J Cancer 2018; 9(10):1731-1736. doi:10.7150/jca.24785. https://www.jcancer.org/v09p1731.htm
Other styles

File import instruction

Abstract

Background: Due to the severity of the primary disease in patients with lung cancer, quality of life (QoL) is often overlooked. Factors that form QoL should be taken in consideration when planning the appropriate treatment and determining therapy targets, because of the increasing frequency of bone metastasis leading to high levels of pain. Purpose of this study is to assess quality of life in patients with lung cancer, before and after treatment combined with zoledronic acid.

Methods and materials: QoL was assessed in 80 patients (49 males-31 females), of which 45 developed bone metastasis. Prior and post treatment (with co administration of zoledronic acid) seven reliable scales: Pittsburgh Sleep Quality index (PSQI), Epworth Sleeping Scale (ess), Dyspnea Scale (ds), Fatigue Severity Scale (FSS), Brief Pain Inventory (BPI), Fact-G scale for sleep quality and EQ-5D for general health condition.

Results: Statistically positive correlations were verified between PSQI-DS, PSQI-FSS, BPI-ESS, DS-FSS, DS-BPI and BPI-FSS (p<0,005) prior and post treatment. Patients sleep quality was improved, pain levels decreased and betterment in quality of life was marked (p<0,001). Although significant decrease in fatigue levels was observed (p<0,001) there has been an increase in dyspnea symptoms (p<0,001).

Conclusions: Significant improvement was apparent when zoledronic acid was co administered in any treatment in patients with lung cancer. Sleep quality, fatigue and pain parameters also improved, with no positive impact on the symptoms of dyspnea.

Keywords: sleep quality, lung cancer, bone metastasis, zoledronic acid


Citation styles

APA
Tremmas, I., Petsatodis, G., Potoupnis, M., Laskou, S., Giannakidis, D., Mantalovas, S., Koulouris, C., Katsaounis, A., Pavlidis, E., Amaniti, A., Huang, H., Bai, C., Shi, D., Dardas, A., Zarogoulidis, P., Sardeli, C., Konstantinou, F., Katsikogiannis, N., Zarogoulidis, K., Karapantzos, I., Karapantzou, C., Shen, X., Kesisoglou, I., Sapalidis, K. (2018). Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires. Journal of Cancer, 9(10), 1731-1736. https://doi.org/10.7150/jca.24785.

ACS
Tremmas, I.; Petsatodis, G.; Potoupnis, M.; Laskou, S.; Giannakidis, D.; Mantalovas, S.; Koulouris, C.; Katsaounis, A.; Pavlidis, E.; Amaniti, A.; Huang, H.; Bai, C.; Shi, D.; Dardas, A.; Zarogoulidis, P.; Sardeli, C.; Konstantinou, F.; Katsikogiannis, N.; Zarogoulidis, K.; Karapantzos, I.; Karapantzou, C.; Shen, X.; Kesisoglou, I.; Sapalidis, K. Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires. J. Cancer 2018, 9 (10), 1731-1736. DOI: 10.7150/jca.24785.

NLM
Tremmas I, Petsatodis G, Potoupnis M, Laskou S, Giannakidis D, Mantalovas S, Koulouris C, Katsaounis A, Pavlidis E, Amaniti A, Huang H, Bai C, Shi D, Dardas A, Zarogoulidis P, Sardeli C, Konstantinou F, Katsikogiannis N, Zarogoulidis K, Karapantzos I, Karapantzou C, Shen X, Kesisoglou I, Sapalidis K. Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires. J Cancer 2018; 9(10):1731-1736. doi:10.7150/jca.24785. https://www.jcancer.org/v09p1731.htm

CSE
Tremmas I, Petsatodis G, Potoupnis M, Laskou S, Giannakidis D, Mantalovas S, Koulouris C, Katsaounis A, Pavlidis E, Amaniti A, Huang H, Bai C, Shi D, Dardas A, Zarogoulidis P, Sardeli C, Konstantinou F, Katsikogiannis N, Zarogoulidis K, Karapantzos I, Karapantzou C, Shen X, Kesisoglou I, Sapalidis K. 2018. Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires. J Cancer. 9(10):1731-1736.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image